These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27895330)

  • 1. FDA approves antitoxin antibody.
    Mullard A
    Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895330
    [No Abstract]   [Full Text] [Related]  

  • 2. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
    Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
    Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezlotoxumab for Preventing Recurrent Clostridium difficile Infections.
    Rounds J; Strain J
    S D Med; 2017 Sep; 70(9):422-423. PubMed ID: 28863256
    [No Abstract]   [Full Text] [Related]  

  • 4. ▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
    Drug Ther Bull; 2018 May; 56(5):57-60. PubMed ID: 29760164
    [No Abstract]   [Full Text] [Related]  

  • 5. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.
    Kelly CP; Wilcox MH; Glerup H; Aboo N; Ellison MC; Eves K; Dorr MB
    Gastroenterology; 2018 Oct; 155(4):1270-1271. PubMed ID: 30227108
    [No Abstract]   [Full Text] [Related]  

  • 7. Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium difficile infection.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):49-50. PubMed ID: 28323808
    [No Abstract]   [Full Text] [Related]  

  • 8. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
    Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
    N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
    Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
    J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clostridium Difficile: Monoclonal Antibody Therapy and Vaccines].
    Reisinger EC; Ebbers M; Löbermann M
    Dtsch Med Wochenschr; 2019 Jun; 144(12):842-849. PubMed ID: 31212328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezlotoxumab: First Global Approval.
    Markham A
    Drugs; 2016 Dec; 76(18):1793-1798. PubMed ID: 27905086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US FDA grants fast-trackdesignation to Sanofi Pasteur's investigational Clostridium difficile vaccine.
    Clin Infect Dis; 2011 Feb; 52(3):i-ii. PubMed ID: 21217176
    [No Abstract]   [Full Text] [Related]  

  • 16. Bezlotoxumab for the Prevention of
    Chahine EB; Cho JC; Worley MV
    Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing Recurrence of C. difficile Infection.
    Dieterle MG; Young VB
    Cell; 2017 Apr; 169(3):375. PubMed ID: 28431238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA approves drug to treat rare hemoglobinuria.
    Thompson CA
    Am J Health Syst Pharm; 2007 May; 64(9):906. PubMed ID: 17468139
    [No Abstract]   [Full Text] [Related]  

  • 20. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.